Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2014; 20(16): 4516-4525
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4516
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4516
Studies (n) | Comparison | Pooled HR (95%CI) | ||
For OS analysis | For DFS analysis1 | OS | DFS | |
17 | 14 | Overall | 0.82 (0.76-0.90) | 0.82 (0.75-0.90) |
2 | 1 | Mono Chemotherapy vs surgery | 0.60 (0.40-0.84) | 0.49 (0.29-0.84) |
3 | 2 | Fluorouracil + mitomycin C + other without anthracyclines vs surgery | 0.74 (0.58-0.95) | 0.69 (0.48-0.98) |
3 | 2 | Fluorouracil + mitomycin C + anthracyclines vs surgery | 0.82 (0.71-0.95) | 0.80 (0.69-0.94) |
- Citation: Miceli R, Tomasello G, Bregni G, Bartolomeo MD, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol 2014; 20(16): 4516-4525
- URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4516.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4516